Adamis says reacquiring from sandoz rights to symjepi products

Adamis pharmaceuticals provides update on symjepi products and announces distribution and commercialization agreement for symjepi and zimhi products.adamis pharmaceuticals -reacquiring from sandoz inc. rights to symjepi injection 0.3mg, injection 0.15mg products currently marketed, available in us.adamis pharmaceuticals- as part of termination agreement, sandoz will continue to support products in u.s. under existing commercialization agreement.adamis-entered into exclusive distribution & commercialization agreement with us worldmeds for us commercial rights for symjepi, zimhi products.adamis-will retain rights to commercialize products outside u.s., may continue to develop its injection platform for additional product candidates.
ADMP Ratings Summary
ADMP Quant Ranking